TLR3 and pulmonary arterial hypertension: Because knockout of type I IFN receptor and type I IFN treatment have frequently been associated with mostly reversible PH in highly preselected patient groups with significant comorbidities (144, 145), further evaluation of TLR3-targeted therapy is required in PAH.